Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Dosing Dilemma For Serum Institute

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

Hand stopping dominos
Stopping Infection Spread Is As Important As Immunizing Individuals • Source: Shutterstock

Soon after University of Oxford and AstraZeneca PLC’s announcement that their COVID-19 vaccine AZD1222 showed 70% efficacy in interim results from Phase III trials, their Indian partner, Serum Institute of India Pvt. Ltd., revealed that it also cut virus spread by 60%.

In the global study conducted by the UK partners, “There were zero hospitalizations in the vaccinated group and the vaccine also brought down by 60% spreading of the virus. So, it grants sterilizing immunity as well and the vaccinated group does not infect others

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By 

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.